Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients

NCT01333358 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Alemtuzumab

Sponsor

Central Texas Neurology Consultants

Collaborators

[object Object]